Buy Rating for Editas Medicine: Promising In Vivo CRISPR Platform and Strategic Growth Potential Amid Speculative Investment
Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...
Promising Financial Position and Advancements Propel Editas Medicine to a ‘Buy’ Rating
JonesTrading analyst Soumit Roy has assigned their bullish stance on EDIT stock, giving a Buy rating today. Soumit Roy’s rating is based ...
GEN19h
“Give Cas a Chance”: Fyodor Urnov Says He Wants a CRISPR Revolution
An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.
ksby21h
Nobel Prize winner Dr. Jennifer Doudna making an appearance in Santa Barbara
Co-hosted by UC Santa Barbara Arts & Lectures and the Cancer Foundation of Santa Barbara, the talk will discuss CRISPR-Cas9 ...
Intellia Therapeutics’ NTLA-2002 Shows Promise with Potential Stock Surge
JonesTrading analyst Debanjana Chatterjee has assigned their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...
Santa Barbara Independent2d
Dr. Jennifer Doudna Talks Editing Genes and Shredding Cancer
UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara host the Nobel Prize–winning biochemist for a talk on CRISPR ...
The New Yorker5d
A Hundred-and-Nineteen-Year-Old Book That Explains Eric Adams
Plunkitt of Tammany Hall,” a collection of political sermons attributed to a crooked machine boss, is a handy reference for ...
Intellia Therapeutics: Promising Outlook with NTLA-2002’s Impressive Phase II Results and Competitive Edge
BMO Capital analyst Kostas Biliouris maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price ...